Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: In the PHF → Ab dosing paradigm, 1D9 IgG1 and IgG2A are the most efficacious subclasses in preventing PHF-induced toxicity and seeding. All 2B8 IgG subclasses are toxic . Mixed JNPL3 cultures were incubated with 10 μg/ml PHF followed 24 h later by 10 µg/ml IgG subclasses (n = at least 6 replicates per condition). Cells were collected 96 h after the antibody application. a. In the 1D9 group, PHF alone increased LDH levels and 1D9 IgG2B had no effect on PHF toxicity (177 and 208 % of control values, p = 0.02 and 0.0008, overall p = 0.0002, one-way ANOVA). In contrast, 1D9 IgG1 prevented PHF toxicity (108% of control, p = 0.05). b. In the 2B8 group, there was an overall treatment effect (p < 0.0001, one-way ANOVA). 2B8 IgG1, IgG2A and IgG2B samples had increased LDH relative to untreated samples (187, 214, and 248% of control values, p = 0.009, = 0.0002, and < 0.0001), and IgG2A and IgG2B treated cells were also elevated compared to PHF alone (p = 0.05, 0.0004). c. Immunoblots showing NeuN levels in the control and treated JNPL3 cultures. d. In the 1D9 group, PHF alone decreased NeuN (43% of control, p < 0.0001, overall p < 0.0001, one-way ANOVA). 1D9 IgG1, IgG2A, and IgG2B prevented this toxicity (NeuN levels 86, 100, and 65% of control values, p < 0.0001, < 0.0001, and 0.04 respectively). e. In the 2B8 group, PHF alone was toxic as measured by NeuN levels (62% of control, p < 0.0001, overall p < 0.0001, one-way ANOVA). None of the 2B8 IgG subtypes prevented the PHF-induced toxicity and had reduced NeuN levels relative to untreated control cells (55, 77, 42, and 34% of control values, P < 0.0001, 0.04, < 0.0001, < 0.0001). f. Immunoblots from the same JNPL3 cell lysate used in the toxicity experiments were probed for total tau. g. In the 1D9 group, PHF alone increased intracellular tau relative to untreated control (ratio tau/NeuN 1.96, p < 0.0001, overall p < 0.0001, one-way ANOVA). 1D9 IgG1, IgG2A and IgG2B prevented tau seeding (ratio tau/NeuN 1.05, 0.97, 1.39, p < 0.0001 compared to PHF alone for all). h. In the 2B8 group, PHF alone increased total tau in the cells (ratio tau/NeuN 1.47, p = 0.016, overall p = 0.0003, one-way ANOVA). Cells treated with 2B8 IgG1, IgG2B and IgG3 also had higher total tau relative to untreated control (ratio tau/NeuN 1.55, 1.68 and 1.61, p = 0.013, 0.0015, and 0.013), and none of the antibodies prevented the PHF-induced tau seeding. i. The same samples were used in immunoblotting to measure tau phosphorylated at Ser199. j. In the 1D9 group, PHF increased intracellular phospho-tau (pSer199/NeuN ratio 2.76, p < 0.0001, overall p < 0.0001, one-way ANOVA). 1D9 IgG1, IgG2A and IgG2B prevented this increase (ratio pSer199/NeuN 1.31, 1.03, and 1.86, p < 0.0001, < 0.0001, 0.03). k. In the 2B8 group, PHF alone increased phospho-tau seeding (ratio pSer199/NeuN 1.93, p = 0.001, overall p < 0.0001, one-way ANOVA). Cells treated with 2B8 IgG1, IgG2A and IgG3 also had an increase in pSer199 relative to the untreated controls (ratio pSer199/NeuN 1.83, 2.11, 2.76, p = 0.013, 0.0005, < 0.0001), with none of the subtypes resulting in different pSer199 levels relative to PHF alone. Bars represent average ± SEM. # p ≤ 0.05, ## p ≤ 0.001, ### p ≤ 0.001, #### p < 0.0001, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p < 0.0001. # significant compared to untreated control, * significant compared to PHF alone.

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: Incubation, Control, Western Blot

Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: 1D9 and 2B8 IgG subclasses bind recombinant-, phosphorylated-, and PHF-tau in solution phase BLI assay . Whole IgG subclasses (Fc-(sdAb) 2 ) were loaded onto Anti-Mouse IgG Fc Capture (AMC) biosensors. K D values were determined using increasing concentration of recombinant- (rec-tau), phosphorylated- (p-tau), and PHF-tau. The IgG subclasses displayed an apparent increased affinity for tau relative to their sdAbs. This results from increased avidity because of bivalent target engagement. a-c. 1D9 IgG1, IgG2A, and IgG2B had 9.6, 7.8-, and 3.9-fold stronger avidity for rec-tau compared to 1D9 sdAb (K D = 4.2 nM, 5.1 nM, and 10.3 nM, respectively). d-f. 2B8 IgG1, IgG2A, and IgG2B had 4.7-, 4.2- and 5.8-fold higher avidity than the sdAb for rec-tau (K D = 3.0 nM, 3.4 nM, and 2.5 nM, respectively). g-i. For p-tau, whole 1D9 IgGs had 3 – 3.6 fold higher avidity relative to their sdAb (K D = 9.1 nM, 11.0 nM, and 10.0 nM for IgG1, IgG2A, and IgG2B, respectively). j-l. The effect of bivalent engagement was also seen with 2B8 in assays with p-tau as IgG1 (8.3 nM), IgG2A (6.8 nM), and IgG2B (11.2 nM) had 4.0-, 4.8-, and 2.9-fold stronger avidity compared to the 2B8 sdAb. m-o. When tested against human derived PHF, 1D9 IgG1, IgG2A, and IgG2B exhibited 2.8-, 3.0-, and 1.9-fold stronger avidity compared to 1D9 sdAb (K D = 8.9 nM, 8.4 nM, and 13.5 nM, respectively). p-r. K D values for 2B8 IgG subclasses were also higher for PHF than their sdAb (14.2 nM, 69.6 nM, and 51.0 nM, for IgG1, IgG2A and IgG2B, respectively). * Due to low Fc binding IgG3 subtypes did not yield results in these tests.

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: Recombinant, Concentration Assay, Derivative Assay, Binding Assay

Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: 1D9 and 2B8 IgG subclasses bind recombinant tau in solid phase BLI assay; 1D9 IgG2B has highest affinity of the subclasses for tau in solid phase ELISA. Only the IgG3 subclass of 1D9 does not bind to PHF-tau in solution. a-h. In the BLI experiments, biosensors were loaded with biotinylated recombinant tau (rec-tau). Association and dissociation of increasing concentrations of whole IgG subtypes were measured and K D values determined. Interestingly, there was no major increase if any in avidity over the unmodified 1D9 and 2B8 sdAbs despite the presence of two binding sites on the whole IgG. a-d. 1D9 subtypes IgG1, IgG2A, IgG2B, and IgG3 had similar K D values (26.0 nM, 39.1 nM, 33.1 nM, and 55.5 nM) that were comparable to 1D9 sdAb (K D = 50.8 nM, see j). e-h. 2B8 subtypes also had similar K D values (37.0 nM, 47.3 nM, 51.9 nM, and 53.3 nM for 2B8 IgG1, IgG2A, IgG2B, and IgG3) that were comparable to 2B8 sdAb (K D = 49.3 nM, see k). i-l. For the standard ELISA, plates were coated with solubilized PHF, sarkosyl insoluble, and sarkosyl soluble tau fractions (1 μg per well). Plates were blocked and then incubated for 3 h with serial dilutions of each 1D9 subtype. i. IgG2B had significantly higher binding than the other subclasses to PHF-tau from 1/40 through 1/25000 (p values from 0.03 to < 0.0001, two-way ANOVA). j. For sarkosyl insoluble tau, 1D9 IgG2B binding was significantly higher than the other subtypes from dilutions 1/40 through 1/5000 (p from 0.03 to < 0.0001, two-way ANOVA). k. On plates coated with sarkosyl soluble tau, 1D9 IgG2B had significantly higher binding at 1/40 (p < 0.0001 for all, two-way ANOVA) and at 1/200 (p = 0.0004 to < 0.0001 for all) and at 1/1000 (p = 0.013 and 0.004 relative to IgG2A and IgG3). l. For the competitive ELISA, plates were coated with solubilized PHF-tau and a single concentration of each of the 1D9 IgG subclass was pre-incubated with increasing concentrations of PHF-tau before adding it to the wells. 1D9 IgG1 had decreased binding to the plate at the two highest PHF concentrations (p = 0.03, < 0.0001, two-way ANOVA) compared to the no PHF control. Plate binding was significantly reduced for 1D9 IgG2A at the three highest PHF pre-incubation concentrations (p = 0.013, 0.004, 0.0014). IgG2B had decreased binding at the two highest PHF concentrations as well (p = 0.03, 0.012). There was no change with IgG3, indicating that it did not bind to PHF-tau in solution. Bars represent average ± SEM. * p ≤ 0.05, ** p ≤ 0.01, **** p < 0.0001, compared to 1D9 IgG2B in panels i-k, and relative to samples receiving no PHF pre-incubation in panel l.

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Binding Assay, Incubation, Competitive ELISA, Concentration Assay, Control

Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: 1D9 subclasses are not toxic in mixed neuron/glia cultures while 2B8 subclasses display toxicity that is dependent on the presence of pathological tau. a-e. Mixed neuron/glia cultures prepared from JNPL3 mice were incubated with 1D9 and 2B8 subtypes alone (10 μg/ml) for 96 h (n = at least 6 replicates per condition). a. There was no significant change in LDH levels in cultures treated with any of the 1D9 subtypes. b. Incubation with 2B8 IgG2A, IgG2B and IgG3 alone increased LDH relative to untreated controls (206, 196, and 176% of control values, p = 0.002, 0.006, 0.046, overall p = 0.003 one-way ANOVA). There was also a strong trend towards increased LDH with 2B8 IgG1 (p = 0.07) c. Immunoblots showing NeuN levels in treated JNPL3 cell lysates. d. None of the 1D9 subtypes altered NeuN levels relative to untreated controls. e. All 2B8 subtypes reduced NeuN levels compared to untreated cells (48, 48, 37, and 46 % of control for IgG1, 2A, 2B and 3, respectively, p ≤ 0.0001 for all, overall p < 0.0001 one-way ANOVA). f. Immunoblots showing NeuN levels in lysates of wild-type cells from mixed neuron/glia cultures treated with 2B8 sdAb. g-h. There were no significant changes in LDH levels (g) or NeuN levels (h) over the 6 day treatment period in the wild-type mouse cells, indicating that the toxic effects seen in the JNPL3 cells in b and e is dependent on pathological tau. Bars represent average ± SEM. # p ≤ 0.05, ### p ≤ 0.001, ##### p < 0.0001, compared to untreated control.

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: Incubation, Control, Western Blot

Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: In the PHF + Ab paradigm, 1D9 IgG1 and IgG2A are the most efficacious subclasses in preventing PHF-induced toxicity and tau seeding, whereas all 2B8 IgG subclasses are toxic or ineffective . Mixed neuron/glia cultures prepared from JNPL3 pups were exposed to 10 µg/ml PHF and 10 μg/ml tau sdAb IgG subclasses added simultaneously (PHF + Ab, n = at least 6 replicates per condition). Cells were collected 96 h following treatment. a. For the 1D9 co-incubation samples, the PHF alone increased LDH levels in culture media (137% of control, p = 0.05, overall p = 0.006, one-way ANOVA). 1D9 IgG1, IgG2A and IgG2B prevented this increase but not 1D9 IgG3 (154% of control, p = 0.01). b. In the co-incubation condition, 2B8 IgG2A, IgG2B and IgG3 had higher LDH levels in the media compared to untreated samples, with IgG2B and IgG3 also significantly higher relative to PHF alone (279, 390, and 293% of control values, p = 0.001, 0.0001, and 0.0011 vs untreated control, p < 0.0001, and 0.04 vs PHF, overall p < 0.0001, one-way ANOVA). c. Immunoblots showing JNPL3 cell lysates probed for NeuN from samples treated with PHF and the IgG sdAb subclasses. d. In the 1D9 group, PHF alone decreased NeuN in cells (56% of control, p < 0.0001, overall p < 0.0001, one-way ANOVA). 1D9 IgG1 and IgG2A prevented PHF-induced toxicity (115 and 112% of control values, p < 0.0001 for both), while IgG2B and 3 did not. e. In the 2B8 group, PHF alone decreased NeuN (50% of control, p < 0.0001, overall p < 0.0001, one-way ANOVA). None of the 2B8 IgG subtypes prevented the PHF-induced toxicity (38, 25, 17, 25 % of control, p < 0.0001 for all). The 2B8 IgG2A, IgG2B, and IgG3 treated samples were also reduced compared to PHF alone (p = 0.03, 0.001, and 0.05). f. Tau immunoblots of the JNPL3 lysate from the same cultures used in the LDH and NeuN quantification. Tau values in g, h, j and k were normalized using NeuN to account for cell loss or retraction. g. In the 1D9 group, PHF alone increased intracellular tau (ratio tau/NeuN 1.94-fold over control, p = 0.0004, overall p < 0.0001, one-way ANOVA). 1D9 IgG1 and IgG2A prevented tau seeding resulting in lower intracellular tau levels relative to PHF alone (ratio tau/NeuN 0.87 and 0.75, p = 0.0016 and 0.0003) while IgG2B and IgG3 had no effect. h. In the 2B8 group, PHF alone increased intracellular tau (tau/NeuN ratio 1.91, p = 0.017, overall p = 0.0002, one-way ANOVA), and none of the 2B8 IgG subclasses prevented tau seeding. 2B8 IgG3 resulted in higher tau levels than in both untreated control and PHF alone cells (ratio tau/NeuN 3.81, p < 0.0001 and = 0.0093 respectively). i. The same JNPL3 lysate was also immunoblotted for tau phosphorylated at Ser199. j. In the 1D9 group, PHF increased intracellular phospho-tau relative to untreated control (ratio pSer199/NeuN 2.28, p = 0.0003, overall p < 0.0001, one-way ANOVA). Both 1D9 IgG1 and IgG2A prevented pathological tau seeding (ratio pSer199/NeuN ratio 0.84 and 0.86, p = 0.0012 and 0.0015). k. In the 2B8 group, IgG2A, IgG2B and IgG3 treated samples all contained higher levels of pSer199 tau than either untreated controls or cells exposed to PHF alone (ratio pSer199/NeuN 4.26, 4.57, and 4.50, p = 0.0005, 0.0001, and 0.0006 relative to untreated samples, p = 0.047, 0.013, and 0.040 relative to PHF alone, overall p < 0.0001, one-way ANOVA). Bars represent average ± SEM. # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, #### p < 0.0001, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.00,1**** p < 0.0001. # significant compared to untreated control, * significant compared to PHF alone .

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: Incubation, Control, Western Blot

Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: 1D9 IgG3 has lower neuronal and microglial uptake relative to other IgG subclasses . Each 1D9 IgG subtype was labeled with CypHer5, a pH sensitive dye that fluoresces in acidic compartments such as the endosomal/lysosomal system. a. Mixed cortical JNPL3 cultures were incubated with 5 µg/ml of the labeled antibodies for one h without addition of exogenous PHF, after which live images were collected from each well (scale = 30 µm). b. The total number of pixels in each image (n = 18 images per group) that contained the antibody signal was determined, and 1D9 IgG3 showed significantly lower uptake compared to all three other subtypes (p < 0.0001 for all, overall p < 0.0001, one-way ANOVA). c. An additional group of cells was fixed and then stained with a total tau antibody to visualize neurons (scale = 20 µm). d. All 1D9 IgG subtypes showed a similar high degree of colocalization between the antibody and neurons (IgG1 75%, IgG2A 62%, IgG2B 65%, and IgG3 71%, n = 20 images per group), indicating that in the absence of exogenous tau, most antibody uptake is neuronal. e. CypHer 5 labeled 1D9 IgG subtypes (5 µg/ml) and human derived PHF-tau (1 μg/ml) were added to mixed neuron/glia cultures at the same time. Cultures were also incubated with fluorescent tomato lectin to label microglia. Live cell images of the cultures showed a high degree of antibody colocalization with glia for 1D9 IgG1, IgG2A and IgG2B after one h incubation (scale = 20 µm). f. Overall uptake in each image (n = 15 images per group) was determined, and 1D9 IgG3 had less uptake than either IgG1 or IgG2B (p = 0.001 and 0.002, overall p = 0.0002, one-way ANOVA). g. 1D9 IgG1, IgG2A and IgG2B showed a shift to a majority microglial uptake in the presence of PHF (82, 77, and 82%). IgG3 in contrast did not and its percentage of microglial uptake was lower relative to the other three (46% colocalization, p = 0.0015, 0.008, and 0.001 for IgG1, IgG2A, and IgG2B, overall p = 0.0003, one-way ANOVA). Bars represent average ± SEM. ** p ≤ 0.05, *** p ≤ 0.001, **** p < 0.0001.

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: Labeling, Incubation, Staining, Derivative Assay

Journal: eBioMedicine

Article Title: Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

doi: 10.1016/j.ebiom.2022.104249

Figure Lengend Snippet: 1D9 IgG1 and IgG2A improve clearance of interstitial tau relative to their sdAb in vivo, whereas the 2B8 IgG subclasses are less effective than their sdAb . Brain interstitial fluid (ISF) was collected from JNPL3 mice aged 7-11 months infused with 1D9 or 2B8 sdAb (n = 6 per group), whole IgG1 or IgG2A (n = 6 per group), or artificial CSF (aCSF) vehicle (n = 11). Baseline samples were collected during the animals’ inactive period, and then for a further 24 hours following antibody administration. The shaded boxes in panels A and C represent the typical dark (awake) cycle for the mice. Even though the animals were maintained in constant light, they display the typical diurnal pattern of tau release during the first 24 h. a. In mice receiving 1D9, there were significant antibody, time, and interaction effects (p < 0.0001, = 0.0088, < 0.0001 respectively, two-way ANOVA). 1D9 sdAb treated animals had lower ISF tau levels relative to untreated controls at 7-10 h post-infusion (p = 0.027 and 0.0055 for 7-8 h and 9-10 h). 1D9 IgG1 infused animals were lower than untreated mice from 3-18 h (p values range from 0.033 through < 0.0001), and IgG2A treated mice from 0-18 h (p values range from 0.045 through < 0.0001). 1D9 IgG1 samples were lower than their sdAb at 5-6 h and 9-10 h (p = 0.035 and 0.025). b. When post-infusion samples were pooled, 1D9 sdAb, IgG1 and IgG2A samples were all lower than untreated control samples (p < 0.0001 for all, overall p < 0.0001, one-way ANOVA). IgG1 and IgG2A were also more effective at preventing the activity related tau increase compared to the sdAb (p < 0.0001 for both). c. In mice receiving 2B8, there were significant treatment, time, and interaction effects (p < 0.0001, = 0.0033, < 0.0001, two-way ANOVA). 2B8 sdAb treated mice had lower ISF tau compared to untreated animals from 0-22 h (p values range from 0.011 through < 0.0001). 2B8 IgG1 treated mice had lower tau levels at 3-14 h (p values range from 0.035 through < 0.0001), and 2B8 IgG2A treated mice only at 5-8 h (p = 0.029 and 0.0001 at 5-6 h and 7-8 h). 2B8 IgG1 values were also higher than its sdAb at 11-12 h and 15-20 h (p values range from 0.048 through 0.0055), and 2B8 IgG2A values were higher at 9-20 h (p values range from 0.035 through < 0.0001). d. All pooled 2B8 sdAb samples had lower ISF tau than untreated controls (p < 0.0001, < 0.0001, = 0.0003, overall p < 0.0001, one-way ANOVA). Post infusion samples from mice treated with 2B8 IgG1 and IgG2A had higher tau levels compared to their sdAb (p = 0.004 and < 0.0001) Points and bars represent average ± SEM. #### p < 0.0001, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p < 0.0001. Panels a and c: * sdAb relative to untreated, * IgG1 relative to untreated, * IgG2A relative to untreated controls. Panels b and d: # significant compared to untreated control, * significant compared to sdAb.

Article Snippet: Axon Neuroscience generated IgG1 and IgG4 variants of AX004, a humanized version of truncated tau antibody DC8E8, and showed that the IgG1 was more effective than the IgG4 in promoting tau uptake in primary human microglial cultures.

Techniques: In Vivo, Control, Activity Assay

Journal: Fundamental Research

Article Title: TRPC5 is essential in endothelium-dependent contraction of aorta from diet-induced obese mice

doi: 10.1016/j.fmre.2022.01.017

Figure Lengend Snippet: Fig. 2. Effect of the TRPC5 activator AM237 on acetylcholine (ACh)-induced relaxation and contraction in the normal-fat diet (NFD) mouse aorta. (a) TRPC5 protein expression in mouse aortic endothelial cells (MAoECs) from NFD ( n = 10) and high-fat diet (HFD)-induced obese ( n = 11) mice. (b) Co-immunostaining of TRPC5 and CD31 in mouse aortic rings (scale bar, 50 𝜇m). (c–e) Representative traces (c) and summary data (d, e) of phenylephrine (Phe)-precontracted ACh-induced relaxation followed by contraction at high concentrations in NFD ( n = 7) and AM237 (100 nmol/L)-pretreated NFD ( n = 6) aortas. (f–h) Original recordings (f) and data summary (g, h) showing the effect of AM237 (100 nmol/L) on ACh-induced contraction in the NFD aorta with or without endothelium ( + endo CTL, n = 5; + endo AM237, n = 5; –endo CTL, n = 4; –endo AM237, n = 4). Mean ± SEM; A, ∗ P < 0.05 vs NFD, Student’s unpaired two-tailed t test; d, ∗ P < 0.05, NS, no significant difference vs NFD, two-way ANOVA followed by Bonferroni test; e, ∗ P < 0.05, NS, no significant difference vs CTL, Student’s unpaired two-tailed t test; g, ∗ P < 0.05 vs + endo CTL, two-way ANOVA followed by Bonferroni test; h, ∗ P < 0.05 vs CTL, # P < 0.05 vs AM237, one-way ANOVA followed by Turkey’s multiple comparisons test.

Article Snippet: The membranes were incubated overnight t 4 °C with the primary antibodies anti-TRPC5 (1:200, Proteintech), nti-COX-1 (1:200, Abcam), anti-COX-2 (1:2000, Abcam), anti-cPLA 2 1:200, Santa Cruz), anti-p-cPLA 2 (1:1000, Signalway Antibody), and nti-GAPDH (1:1000, Santa Cruz) followed by horseradish peroxidaseonjugated secondary antibody (mouse, 1:10,000; rabbit, 1:5000, Beytime) at room temperature for 2 h. ImageJ was used for band intensity nalysis.

Techniques: Expressing, Immunostaining, Two Tailed Test

Journal: Fundamental Research

Article Title: TRPC5 is essential in endothelium-dependent contraction of aorta from diet-induced obese mice

doi: 10.1016/j.fmre.2022.01.017

Figure Lengend Snippet: Fig. 3. Effect of TRPC5 inhibition on acetylcholine (ACh)-induced vaso- constriction in the high-fat diet (HFD)-induced obese mouse aorta. (a, b) Representative traces (a) and data summary (b) showing ACh-induced contrac- tion is attenuated by the TRPC5 inhibitor clemizole (20 𝜇mol/L), knockout of TRPC5, and the removal of endothelium (CTL, n = 5; clemizole, n = 6; TRPC5 − / − , n = 5; CTL(–Endo), n = 6; mean ± SEM; b, left, ∗ P < 0.05 vs CTL, two-way ANOVA followed by Bonferroni test; right, ∗ P < 0.05 vs CTL, one-way ANOVA followed by Dunnett’s multiple comparisons test).

Article Snippet: The membranes were incubated overnight t 4 °C with the primary antibodies anti-TRPC5 (1:200, Proteintech), nti-COX-1 (1:200, Abcam), anti-COX-2 (1:2000, Abcam), anti-cPLA 2 1:200, Santa Cruz), anti-p-cPLA 2 (1:1000, Signalway Antibody), and nti-GAPDH (1:1000, Santa Cruz) followed by horseradish peroxidaseonjugated secondary antibody (mouse, 1:10,000; rabbit, 1:5000, Beytime) at room temperature for 2 h. ImageJ was used for band intensity nalysis.

Techniques: Inhibition, Knock-Out

Journal: Fundamental Research

Article Title: TRPC5 is essential in endothelium-dependent contraction of aorta from diet-induced obese mice

doi: 10.1016/j.fmre.2022.01.017

Figure Lengend Snippet: Fig. 4. TRPC5 regulates contractions via cytosolic phospholipase A 2 (cPLA 2 ) in the high-fat diet (HFD)-induced obese mouse aorta. (a) Western blots and analysis of cPLA 2 and phosphorylated cPLA 2 (p-cPLA 2 ) expression in normal-fat diet (NFD, n = 15), AM237 (100 nmol/L)-treated NFD ( n = 9), HFD-induced obese ( n = 14), clemizole (20 𝜇mol/L)-treated HFD ( n = 7), and TRPC5 − / − -HFD ( n = 5) mouse aortic endothelial cells (MAoECs). (b) Dose-dependent effect of AM237 on p-cPLA 2 levels in NFD MAoECs. AM237 (nmol/L), 0, n = 16; 50, n = 11; 100, n = 16; 200, n = 10. (c) Dose-dependent effect of clemizole on p-cPLA 2 levels in HFD MAoECs ( n = 5). (d) Representative fluorescence images of the Bis-BODIPY TM FL C 11 -PC stained en-face aorta and analysis of PLA 2 activity in endothelial cells of the NFD ( n = 9), AM237 (100 nmol/L)-pretreated NFD ( n = 7), HFD ( n = 17), clemizole (20 𝜇mol/L)-treated HFD ( n = 9), and TRPC5 − / − HFD ( n = 12) mouse aorta (scale bars, 10 𝜇m). (e) Acetylcholine (ACh)-induced contraction in HFD ( n = 4) and MAFP (10 𝜇mol/L)-treated HFD ( n = 6) mouse aortic rings. (f) ACh-induced contraction in the NFD ( n = 5), AM237 (100 nmol/L)-pretreated NFD ( n = 5), and AM237 (100 nmol/L) + MAFP (30 𝜇mol/L)-pretreated NFD ( n = 6) mouse aorta. Mean ± SEM; a, ∗ P < 0.05 vs NFD, # P < 0.05 vs HFD, NS, no significant difference, Kruskal-Wallis and Dunn’s post hoc non-parametric test (p-cPLA 2 ) and one-way ANOVA followed by Turkey’s multiple comparisons test (cPLA 2 ); b, ∗ P < 0.05, NS, no significant difference vs no AM237, one-way ANOVA followed by Dunnett’s multiple comparisons test; c, ∗ P < 0.05, NS, no significant difference vs no clemizole, one-way ANOVA followed by Dunnett’s multiple comparisons test; d, ∗ P < 0.05 vs NFD, # P < 0.05 vs HFD, one-way ANOVA followed by Turkey’s multiple comparisons test; e, ∗ P < 0.05 vs CTL, two-way ANOVA followed by Bonferroni test (left) and Student’s unpaired two-tailed t test (right); f, ∗ P < 0.05 vs CTL, # P < 0.05 vs AM237, two-way ANOVA followed by Bonferroni test (left) and one-way ANOVA followed by Turkey’s multiple comparisons test (right).

Article Snippet: The membranes were incubated overnight t 4 °C with the primary antibodies anti-TRPC5 (1:200, Proteintech), nti-COX-1 (1:200, Abcam), anti-COX-2 (1:2000, Abcam), anti-cPLA 2 1:200, Santa Cruz), anti-p-cPLA 2 (1:1000, Signalway Antibody), and nti-GAPDH (1:1000, Santa Cruz) followed by horseradish peroxidaseonjugated secondary antibody (mouse, 1:10,000; rabbit, 1:5000, Beytime) at room temperature for 2 h. ImageJ was used for band intensity nalysis.

Techniques: Western Blot, Expressing, Staining, Activity Assay, Two Tailed Test

Journal: Fundamental Research

Article Title: TRPC5 is essential in endothelium-dependent contraction of aorta from diet-induced obese mice

doi: 10.1016/j.fmre.2022.01.017

Figure Lengend Snippet: Fig. 6. Role of COX-2 in TRPC5-regulated vasoconstriction in the mouse aorta. (a) Western blots and analysis of COX-1 and COX-2 expression in normal-fat diet (NFD, n = 5), AM237 (100 nmol/L) pre-treated NFD ( n = 5), high-fat diet (HFD, n = 5), clemizole (20 𝜇mol/L) pre-treated HFD ( n = 5), and TRPC5 − / − HFD ( n = 5) mouse aortic endothelial cells (MAoECs). (b) Effect of the COX inhibitors NS-398 (3 𝜇mol/L) ( n = 5), VAS-2870 (30 𝜇mol/L) ( n = 3), and indomethacin (indo, 1 𝜇mol/L, n = 3) on acetylcholine (ACh)-induced contraction in the HFD mouse aorta (CTL, n = 3). (c) Effect of the COX-2 inhibitor NS-398 (3 𝜇mol/L) on ACh-induced contraction in the AM237 (100 nmol/L)-pretreated NFD mouse aorta (CTL, n = 5; AM237, n = 7; AM237 + NS-398, n = 7). Mean ± SEM; a, ∗ P < 0.05 vs NFD, # P < 0.05 vs HFD, NS, no significant difference, Kruskal-Wallis and Dunn’s post hoc non-parametric test (COX-1) and one-way ANOVA followed by Turkey’s multiple comparisons test (COX-2); b, ∗ P < 0.05, NS, no significant difference vs CTL, two-way ANOVA followed by Bonferroni test (left) and one-way ANOVA followed by Dunnett’s multiple comparisons test (right); c, ∗ P < 0.05 vs CTL, # P < 0.05 vs AM237, two-way ANOVA followed by Bonferroni test (left) and one-way ANOVA followed by Turkey’s multiple comparisons test (right) .

Article Snippet: The membranes were incubated overnight t 4 °C with the primary antibodies anti-TRPC5 (1:200, Proteintech), nti-COX-1 (1:200, Abcam), anti-COX-2 (1:2000, Abcam), anti-cPLA 2 1:200, Santa Cruz), anti-p-cPLA 2 (1:1000, Signalway Antibody), and nti-GAPDH (1:1000, Santa Cruz) followed by horseradish peroxidaseonjugated secondary antibody (mouse, 1:10,000; rabbit, 1:5000, Beytime) at room temperature for 2 h. ImageJ was used for band intensity nalysis.

Techniques: Western Blot, Expressing

Journal: Fundamental Research

Article Title: TRPC5 is essential in endothelium-dependent contraction of aorta from diet-induced obese mice

doi: 10.1016/j.fmre.2022.01.017

Figure Lengend Snippet: Fig. 5. TRPC5 contributes to acetylcholine (ACh)-induced Ca 2+ entry into endothelial cells of high-fat diet (HFD)-induced obese mouse aortas. (a, b) Representative traces (a) and data summary (b) showing an ACh (10 𝜇mol/L)- induced [Ca 2 + ] i rise in aortic endothelial cells from normal-fat diet (NFD) and HFD mice (NFD, n = 7; NFD-AM237 (100 nmol/L), n = 5; HFD, n = 5; HFD- clemizole (20 𝜇mol/L), n = 6; HFD-TRPC5 − / − , n = 6; mean ± SEM; ∗ P < 0.05 vs NFD, # P < 0.05 vs HFD, one-way ANOVA followed by Turkey’s multiple com- parisons test).

Article Snippet: The membranes were incubated overnight t 4 °C with the primary antibodies anti-TRPC5 (1:200, Proteintech), nti-COX-1 (1:200, Abcam), anti-COX-2 (1:2000, Abcam), anti-cPLA 2 1:200, Santa Cruz), anti-p-cPLA 2 (1:1000, Signalway Antibody), and nti-GAPDH (1:1000, Santa Cruz) followed by horseradish peroxidaseonjugated secondary antibody (mouse, 1:10,000; rabbit, 1:5000, Beytime) at room temperature for 2 h. ImageJ was used for band intensity nalysis.

Techniques:

Journal: Fundamental Research

Article Title: TRPC5 is essential in endothelium-dependent contraction of aorta from diet-induced obese mice

doi: 10.1016/j.fmre.2022.01.017

Figure Lengend Snippet: Fig. 7. PGF 2 𝜶and PGE 2 are involved in TRPC5-related contraction in the high-fat diet (HFD)-induced obese mouse aorta. (a) Enzyme immunoassay (EIA) showing the PGF 2 𝛼( n = 7), PGE 2 ( n = 7), PGD 2 ( n = 5), PGI 2 ( n = 5), and 8-isoprostanes ( n = 6) levels in normal-fat diet (NFD) and HFD mouse aortic rings after exposure to acetylcholine (ACh, 10 𝜇mol/L). (b) Effect of clemizole (20 𝜇mol/L), MAFP (10 𝜇mol/L), NS-398 (3 𝜇mol/L), –endo, and knockout of TRPC5 − / − on ACh-induced PGF 2 𝛼and PGE 2 release in the ACh-stimulated HFD mouse aorta (PGF 2 𝛼, CTL, n = 7; clemizole, n = 5; TRPC5 − / − , n = 5; MAFP, n = 6; NS-398, n = 6; –endo, n = 6; PGE 2 , CTL, n = 7; clemizole, n = 5; TRPC5 − / − , n = 5; MAFP, n = 5; NS-398, n = 5; –endo, n = 5; (c) Effects of AM237 (100 nmol/L), MAFP (10 𝜇mol/L), and NS-398 (3 𝜇mol/L) treatment and the removal of endothelium (–Endo) on EIA for PGF 2 𝛼and PGE 2 in the NFD mouse aorta stimulated with ACh (10 𝜇mol/L) (PGF 2 𝛼, CTL, n = 7; AM237, n = 4; MAFP, n = 6; NS-398, n = 4; –endo, n = 4; PGE 2 , CTL, n = 10; AM237, n = 5; MAFP, n = 5; NS-398, n = 5; –endo, n = 7). (d) Schematic of the mechanism of TRPC5 regulation of endothelium-dependent contraction in the DIO mouse aorta. Mean ± SEM; a, ∗ P < 0.05, NS, no significant difference vs NFD, Student’s unpaired two-tailed t test; b, ∗ P < 0.05 vs CTL, one-way ANOVA followed by Dunnett’s multiple comparisons test; c, ∗ P < 0.05 vs CTL, # P < 0.05 vs AM237 group, one-way ANOVA followed by Turkey’s multiple comparisons test.

Article Snippet: The membranes were incubated overnight t 4 °C with the primary antibodies anti-TRPC5 (1:200, Proteintech), nti-COX-1 (1:200, Abcam), anti-COX-2 (1:2000, Abcam), anti-cPLA 2 1:200, Santa Cruz), anti-p-cPLA 2 (1:1000, Signalway Antibody), and nti-GAPDH (1:1000, Santa Cruz) followed by horseradish peroxidaseonjugated secondary antibody (mouse, 1:10,000; rabbit, 1:5000, Beytime) at room temperature for 2 h. ImageJ was used for band intensity nalysis.

Techniques: Enzyme-linked Immunosorbent Assay, Knock-Out, Two Tailed Test

Journal: Fundamental Research

Article Title: Engineered In-Situ-Forming Biomimetic Hydrogel with Self-Regulated Immunostimulatory Capacity Promotes Postoperative Tumor Treatment

doi: 10.1016/j.fmre.2023.02.029

Figure Lengend Snippet: Fig. 3. Ferroptosis-inducing and immunostimulatory capabilities of the biomimetic hydrogel. (a) Schematic diagram for the tumor cell/immune cell co- incubation system in transwell plates. The tumor cells (B16F10, 4T1) or immune cells were inoculated in the bottom chamber of the 24-well transwell culture plate, while the hydrogel soaking solution was placed in the upper chamber. (b) Changes of GPX4 activity in B16F10 cells after different treatments. (I) Control, (II) Gel, (III) RSL3, (IV) Gel@RSL3 (n = 4). (c) Flow cytometric analysis on the lipid ROS levels in B16F10 cells after different treatments. (d) CLSM imaging of lipid ROS generation in B16F10 cells after different treatments. Higher green fluorescence intensity indicates greater lipid ROS production. (e) Quantitative fluorescence analysis of lipid ROS levels in panel D (n = 4). (f) Flow cytometric analysis on the hydrogel-mediated ferroptosis levels of B16F10 cells after different treatments. (g) ATP levels in the supernatants of cell culture after different treatments. (I) Control, (II) Gel, (III) RSL3, (IV) Gel@RSL3 (n = 4). (h) CLSM imaging of CRT expression in B16F10 cells after different treatments. Stronger red fluorescence indicates higher expression levels. (i) Quantitative fluorescence analysis of CRT expression levels in panel H (n = 4). (j) CLSM imaging of cellular HMGB1 abundance after different treatments. Lower red fluorescence indicates greater HMGB1 release into the extracellular compartment. (k) Quantitative fluorescence analysis of HMGB1 release in panel J (n = 4). (l) Flow cytometric analysis on the treatment-induced maturation of BMDCs. (m) Flow cytometric analysis on the activation status of macrophages by monitoring the CD80 expression levels. ∗ indicates significance at P < 0.05, ∗ ∗ indicates significance at P < 0.01.

Article Snippet: RT, HMGB1, and SLC7A11 were supplied by Proteintech (Wuhan, hina).

Techniques: Incubation, Activity Assay, Control, Imaging, Cell Culture, Expressing, Activation Assay

Journal: Fundamental Research

Article Title: Engineered In-Situ-Forming Biomimetic Hydrogel with Self-Regulated Immunostimulatory Capacity Promotes Postoperative Tumor Treatment

doi: 10.1016/j.fmre.2023.02.029

Figure Lengend Snippet: Fig. 4. Gel@RSL3 + GM-CSF + aPD-L1 activates immune response in vitro. (a-d) Flow cytometric analysis of the activation status of DCs (CD11c + /MHC II + ), M1 macrophages (F4/80 + /CD80 + ) and T cells (CD8 + /CD3 + and CD8a + /IFN- 𝛾+ ) in the co-incubation system of splenic immune cells and B16F10 cells after treatment with (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3 and (V) Gel@RSL3 + GM-CSF (n = 4). (e) Secretion levels of immunostimulatory cytokines including IFN- 𝛾, TNF- 𝛼and antitumor effector molecule GzmB in the supernatant from the co-culture system after different treatments (n = 4). (f) PD-L1 expression in tumor cells with after the hydrogel-mediated ferroptosis-immunotherapy. Group set-up for panel e-f: (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3 and (V) Gel@RSL3 + GM- CSF). (g-h) Flow cytometric analysis of the expression levels of effector T cell marker CD4 + /CD8 + and CD8a + /IFN- 𝛾+ in T cells co-incubated with B16F10 cells after treatment with (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3, (V) Gel@RSL3 + GM-CSF and (VI) Gel@RSL3 + GM-CSF + aPD-L1. (i) Secretion levels of immunostimulatory cytokines including IFN- 𝛾, TNF- 𝛼and antitumor effector molecule GzmB in the supernatant from the co-culture system after different treatments (n = 4). (j) Evaluation on the GSH levels in B16F10 cells after different treatments (n = 4). (k) Western blot analysis of the expression level of CRT, HMGB1 and SLC7A11 in different groups. (l) Flow cytometric analysis on the lipid ROS levels in B16F10 cells after different treatments. (m) MDA levels in B16F10 cells after different treatments (n = 4). Group set-up for panel I-M: (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3, (V) Gel@RSL3 + GM-CSF and (VI) Gel@RSL3 + GM-CSF + aPD- L1). (n) Flow cytometric analysis on the death rate of B16F10 cells after different treatments, including (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3, (V) Gel@RSL3 + GM-CSF and (VI) Gel@RSL3 + GM-CSF + aPD-L1. ∗ indicates significance at P < 0.05, ∗ ∗ indicates significance at P < 0.01, ∗ ∗ ∗ indicates significance at P < 0.001, ∗ ∗ ∗ ∗ indicates significance at P < 0.0001.

Article Snippet: RT, HMGB1, and SLC7A11 were supplied by Proteintech (Wuhan, hina).

Techniques: In Vitro, Activation Assay, Incubation, Control, Co-Culture Assay, Expressing, Marker, Western Blot

Journal: Fundamental Research

Article Title: Engineered In-Situ-Forming Biomimetic Hydrogel with Self-Regulated Immunostimulatory Capacity Promotes Postoperative Tumor Treatment

doi: 10.1016/j.fmre.2023.02.029

Figure Lengend Snippet: Fig. 5. Antitumor effect of biomimetic hydrogel in vivo. (a) Schematic illustration of the treatment scheme of the B16F10-luc tumor-bearing mice (n = 7). (b) Treatment procedures on the tumor-bearing mice. (c) In vivo bioluminescence images of B16F10-luc tumor-bearing mice throughout the treatment period with (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3, (V) Gel@RSL3 + GM-CSF and (VI) Gel@RSL3 + GM-CSF-aPD-L1. (d) Tumor size changes during the incubation period after different treatments. (e) Survival analysis of mice after different treatments. (f) Body weight changes after treatment with different samples. (g) Evaluation on the GPX4 activity in tumor tissues after different treatments (n = 4). (h) Western blot analysis on the expression of CRT, HMGB1 and SLC7A11 in B16F10-luc tumors after treatment with (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3, (V) Gel@RSL3 + GM-CSF and (VI) Gel@RSL3 + GM-CSF-aPD-L1. (i) MDA levels in tumor tissue after different treatments (n = 4). (j) H&E and TUNEL staining of tumor tissue samples after treatment (I) Control, (II) Gel, (III) Gel@GM-CSF, (IV) Gel@RSL3, (V) Gel@RSL3 + GM-CSF and (VI) Gel@RSL3 + GM-CSF-aPD-L1. ∗ indicates significance at P < 0.05, ∗ ∗ indicates significance at P < 0.01, ∗ ∗ ∗ indicates significance at P < 0.001.

Article Snippet: RT, HMGB1, and SLC7A11 were supplied by Proteintech (Wuhan, hina).

Techniques: In Vivo, Control, Incubation, Activity Assay, Western Blot, Expressing, TUNEL Assay, Staining

Journal: Fundamental Research

Article Title: O-GlcNAcylation of YTHDF2 antagonizes ERK-dependent phosphorylation and inhibits lung carcinoma

doi: 10.1016/j.fmre.2024.07.003

Figure Lengend Snippet: Fig. 2 O-GlcNAcylation of YTHDF2 at Thr-49 antagonizes ERK-dependent

Article Snippet: The following primary antibodies were used for immunoblot: anti-Myc (PTM Bio, #PTM-5390, 1:3000), anti-c-Myc (ProteinTech, #10828-1-AP, 1:1000), anti-YTHDF2 (proteinTech, #24744-1-AP, 1:1000), anti-Flag (Sigma, #F1084, 1:1000), RL2 (Abcam, #AB2739, 1:1000), anti-GST (Gene Script, #A00865, 1:1000), anti-HA (Bethyl, #A190-108A, 1:1000), anti-OGT (Santa Cruz Biotechnology, #sc-74546, 1:1000), anti-β-actin (Sigma, #A5441, 1:1000), anti-Ubiquitin (PTM Bio, #PTM-1106RM, 1:1000) , anti-AXIN (ProteinTech,#16541-1-AP, 1:1000) and anti-YTHDF2-pS39 antibodies were generated using the sequence PYLpSPQAR by Dia-An Biotech, Inc. Peroxidase-conjugated secondary antibodies were from JacksonImmuno Research.

Techniques:

Journal: Fundamental Research

Article Title: O-GlcNAcylation of YTHDF2 antagonizes ERK-dependent phosphorylation and inhibits lung carcinoma

doi: 10.1016/j.fmre.2024.07.003

Figure Lengend Snippet: Fig. 3 YTHDF2 O-GlcNAcylation promotes ubiquitination. (a) 293T cells were

Article Snippet: The following primary antibodies were used for immunoblot: anti-Myc (PTM Bio, #PTM-5390, 1:3000), anti-c-Myc (ProteinTech, #10828-1-AP, 1:1000), anti-YTHDF2 (proteinTech, #24744-1-AP, 1:1000), anti-Flag (Sigma, #F1084, 1:1000), RL2 (Abcam, #AB2739, 1:1000), anti-GST (Gene Script, #A00865, 1:1000), anti-HA (Bethyl, #A190-108A, 1:1000), anti-OGT (Santa Cruz Biotechnology, #sc-74546, 1:1000), anti-β-actin (Sigma, #A5441, 1:1000), anti-Ubiquitin (PTM Bio, #PTM-1106RM, 1:1000) , anti-AXIN (ProteinTech,#16541-1-AP, 1:1000) and anti-YTHDF2-pS39 antibodies were generated using the sequence PYLpSPQAR by Dia-An Biotech, Inc. Peroxidase-conjugated secondary antibodies were from JacksonImmuno Research.

Techniques: Ubiquitin Proteomics

Journal: Fundamental Research

Article Title: O-GlcNAcylation of YTHDF2 antagonizes ERK-dependent phosphorylation and inhibits lung carcinoma

doi: 10.1016/j.fmre.2024.07.003

Figure Lengend Snippet: Fig. 4 O-GlcNAcylation of YTHDF2 downregulates c-Myc in H1299 and A549 lung

Article Snippet: The following primary antibodies were used for immunoblot: anti-Myc (PTM Bio, #PTM-5390, 1:3000), anti-c-Myc (ProteinTech, #10828-1-AP, 1:1000), anti-YTHDF2 (proteinTech, #24744-1-AP, 1:1000), anti-Flag (Sigma, #F1084, 1:1000), RL2 (Abcam, #AB2739, 1:1000), anti-GST (Gene Script, #A00865, 1:1000), anti-HA (Bethyl, #A190-108A, 1:1000), anti-OGT (Santa Cruz Biotechnology, #sc-74546, 1:1000), anti-β-actin (Sigma, #A5441, 1:1000), anti-Ubiquitin (PTM Bio, #PTM-1106RM, 1:1000) , anti-AXIN (ProteinTech,#16541-1-AP, 1:1000) and anti-YTHDF2-pS39 antibodies were generated using the sequence PYLpSPQAR by Dia-An Biotech, Inc. Peroxidase-conjugated secondary antibodies were from JacksonImmuno Research.

Techniques:

Journal: Fundamental Research

Article Title: O-GlcNAcylation of YTHDF2 antagonizes ERK-dependent phosphorylation and inhibits lung carcinoma

doi: 10.1016/j.fmre.2024.07.003

Figure Lengend Snippet: Fig. 5 O-GlcNAcylation of YTHDF2 regulates the metastatic capacity of H1299 and

Article Snippet: The following primary antibodies were used for immunoblot: anti-Myc (PTM Bio, #PTM-5390, 1:3000), anti-c-Myc (ProteinTech, #10828-1-AP, 1:1000), anti-YTHDF2 (proteinTech, #24744-1-AP, 1:1000), anti-Flag (Sigma, #F1084, 1:1000), RL2 (Abcam, #AB2739, 1:1000), anti-GST (Gene Script, #A00865, 1:1000), anti-HA (Bethyl, #A190-108A, 1:1000), anti-OGT (Santa Cruz Biotechnology, #sc-74546, 1:1000), anti-β-actin (Sigma, #A5441, 1:1000), anti-Ubiquitin (PTM Bio, #PTM-1106RM, 1:1000) , anti-AXIN (ProteinTech,#16541-1-AP, 1:1000) and anti-YTHDF2-pS39 antibodies were generated using the sequence PYLpSPQAR by Dia-An Biotech, Inc. Peroxidase-conjugated secondary antibodies were from JacksonImmuno Research.

Techniques:

Journal: Fundamental Research

Article Title: O-GlcNAcylation of YTHDF2 antagonizes ERK-dependent phosphorylation and inhibits lung carcinoma

doi: 10.1016/j.fmre.2024.07.003

Figure Lengend Snippet: Fig. 6 YTHDF2 O-GlcNAcylation inhibits lung cancer. (a-c) Xenografts in nude mice.

Article Snippet: The following primary antibodies were used for immunoblot: anti-Myc (PTM Bio, #PTM-5390, 1:3000), anti-c-Myc (ProteinTech, #10828-1-AP, 1:1000), anti-YTHDF2 (proteinTech, #24744-1-AP, 1:1000), anti-Flag (Sigma, #F1084, 1:1000), RL2 (Abcam, #AB2739, 1:1000), anti-GST (Gene Script, #A00865, 1:1000), anti-HA (Bethyl, #A190-108A, 1:1000), anti-OGT (Santa Cruz Biotechnology, #sc-74546, 1:1000), anti-β-actin (Sigma, #A5441, 1:1000), anti-Ubiquitin (PTM Bio, #PTM-1106RM, 1:1000) , anti-AXIN (ProteinTech,#16541-1-AP, 1:1000) and anti-YTHDF2-pS39 antibodies were generated using the sequence PYLpSPQAR by Dia-An Biotech, Inc. Peroxidase-conjugated secondary antibodies were from JacksonImmuno Research.

Techniques:

Journal: Current Research in Food Science

Article Title: A Pectic Polysaccharide from Lycium ruthenicum Murray Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice

doi: 10.1016/j.crfs.2024.100955

Figure Lengend Snippet: Fig. 4. Effects of LRWP-Ap on pathological changes and TJ protein expression and on the balance of Arg-1/iNOS in mouse colon tissues. (A&B) H&E staining of mouse colon tissue. H&E staining (A) and colonic tissue damage score (B). (C–F) Western blot analysis of TJ protein and β-actin protein expression in colon tissues. Grayscale intensity statistics for Claudin 1 (D), Occludin (E), and ZO-1 (F) protein expression. (G–I) Immunofluorescence images of Arg-1, iNOS, and DAPI in paraffin- embedded colon tissue sections from each group. Relative fluorescence intensity of Arg-1 (H) and iNOS (I). L–A: LRWP-Ap. The data are expressed as the means ± standard deviations (n = 3, randomly selected from 6). *P < 0.05 and **P < 0.01 vs. the control group. #P < 0.05 and ##P < 0.01 vs. the model group.

Article Snippet: The membrane was blocked with a Rapid Closure Solution (GeneFist, Shanghai, China) for 30 min, then incubated overnight at 4◦Cwith primary antibodies against ZO-1, Occludin, Claudin-1, and β-actin (Proteintech, Hubei, China).

Techniques: Expressing, Staining, Western Blot, Immunofluorescence, Fluorescence, Control